Abstract:BACKGROUNDThe objective of this study was to investigate the antitumor activity of selectively expanded gammadelta T cells in tumor-infiltrating lymphocytes (gammadeltaTILs) or tumor ascites lymphocytes (gammadeltaTALs) from patients with colorectal and ovarian epithelial carcinoma (OEC) in vitro and in vivo.METHODSgammadeltaTILs/TALs were expanded by the solid-phase antibody method; their cytolytic and proliferative activities in vitro were detected by the MTT method and 3H-TdR incorporation and their effect in vivo was evaluated by the nude mice model.RESULTSExpanded gammadeltaTILs from colorectal tumors demonstrated marked cytotoxicities to allogeneic human colon adenocarcinoma HR8348 and lymphoma Daudi cells, as well as xenogeneic murine thymoma EL-4 cell lines. Cytokines, including IL-2, IL-4, IL-12, IL-15, TNF-alpha and INF-gamma, could promote the cytotoxicities of gammadeltaTILs to tumor cells, whereas IL-10, GM-CSF and TFG-beta had no effect on such killing activities. Rested gammadeltaTILs could proliferate strongly in response to mitomycin C-treated Daudi and EL-4 tumor cells, but not to HR8348 tumor cells, suggesting that the latter might possess only cytotoxicity-related antigen recognized by gammadeltaTILs. Either alphabetaTILs or gammadeltaTILs from patients with OEC displayed cytotoxicities to allogeneic or autologous OEC cell lines at a similar strength in vitro. Transferring gammadeltaTILs into Daudi cell-bearing BALB/c nude mice with an injection of IL-2 was able to maintain a high survival rate of the mice for 30 days, when compared with mice treated with alphabetaTILs or without any treatment (p < 0.05). Without coinjection of IL-2, after 3 months of Daudi tumor inoculation, a high survival rate was observed in gammadeltaTIL-treated mice. Similarly, adoptive gammadeltaTALs from the ascites of patients with OEC transferred into nude mice displayed a stronger antitumor response to OEC SKOV3 cells than alphabetaTALs in vivo. Tumor volumes in gammadeltaTAL-treated mice were smaller than in alphabetaTAL-treated or non-TAL-treated mice within the period from day 23 to day 50 after tumor inoculation (p < 0.05). Fifty days after SKOV3 tumor inoculation, a decreasing trend of carcinogenic rate was observed in gammadeltaTAL-treated nude mice.CONCLUSIONTaken together, our results suggest that gammadeltaT cells could be a new candidate for adoptive immunotherapy in the future treatment of patients with cancer.

HMGN2: an Antitumor Effector Molecule of Γδt Cells

Effect of γδT Cells in Tumor

Expansion and Immunological Study of Human Tumor Infiltrating Gamma/Delta T Lymphocytes in vitro<sup>1</sup>

Antitumor Activity of Expanded Human Tumor-Infiltrating Gammadelta T Lymphocytes.

Recombinant Jurkat Cells (HMGN2-T Cells) Secrete Cytokines and Inhibit the Growth of Tumor Cells

Identification of Human T Cell Receptor Γδ-Recognized Epitopes/Proteins Via CDR3δ Peptide-based Immunobiochemical Strategy

Nucleosome-binding protein HMGN2 exhibits antitumor activity in oral squamous cell carcinoma.

HMGN2 Protein Inhibits the Growth of Infected T24 Cells in Vitro.

Nuclear HMGB1 is Critical for CD8 T Cell IFN-γ Production and Anti-Tumor Immunity

HMGB1 Knockdown Increases MM Cell Vulnerability by Regulating Autophagy and DNA Damage Repair

Study on the effect of γδ T cells expanded in vitro to kill hepatocellular carcinoma cells

Natural killer (NK) cell high-mobility group box 1 (HMGB1) is required for anti-tumor function (TUM2P.895)

Increased Expression of High-Mobility Group Nucleosomal-Binding Domain 2 Protein in Various Tumor Cell Lines.

γδ T cells as critical anti-tumor immune effectors

γδ T Cells in the Tumor Microenvironment—Interactions With Other Immune Cells

Research Progress of γδT Cells in Tumor Immunotherapy

Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2+ T Cells in the Presence of Costimulation by CD28 or NKG2D

An exploratory study on the amplification of tumor cell specific γ δ T cells and its anti-tumor activities

Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application

CD69 + Vδ1γδ T cells are anti-tumor subpopulations in hepatocellular carcinoma

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future